Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Chimerix ( (CMRX) ).
Chimerix, a biopharmaceutical company, reported its third-quarter 2024 financial results, highlighting significant progress in its Phase 3 ACTION study for dordaviprone, with interim survival data expected in 2025. The study received a safety recommendation from the IDMC, and the company is preparing for provisional drug registration in Australia. Chimerix also promoted Dr. Josh Allen to Chief Scientific Officer, underscoring his contributions to cancer drug development. Financially, the company reported a net loss of $22.9 million and an increase in research expenses, with a strong balance sheet holding $152.4 million in capital.
For a thorough assessment of CMRX stock, go to TipRanks’ Stock Analysis page.
